Bard Financial Services Inc. Cuts Stake in Novo Nordisk A/S $NVO

Bard Financial Services Inc. reduced its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 13.9% during the third quarter, Holdings Channel reports. The fund owned 60,275 shares of the company’s stock after selling 9,695 shares during the period. Bard Financial Services Inc.’s holdings in Novo Nordisk A/S were worth $3,345,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in NVO. NewSquare Capital LLC grew its holdings in shares of Novo Nordisk A/S by 174.1% during the 2nd quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares during the last quarter. Mid American Wealth Advisory Group Inc. bought a new position in shares of Novo Nordisk A/S during the second quarter valued at about $37,000. State of Wyoming purchased a new position in shares of Novo Nordisk A/S in the first quarter worth about $38,000. Maseco LLP purchased a new position in shares of Novo Nordisk A/S in the second quarter worth about $39,000. Finally, Copeland Capital Management LLC lifted its stake in shares of Novo Nordisk A/S by 47.3% in the 2nd quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock valued at $40,000 after acquiring an additional 186 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on NVO shares. The Goldman Sachs Group decreased their price target on Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating on the stock in a research note on Friday, November 28th. Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 16th. HSBC reiterated a “hold” rating and set a $54.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Rothschild & Co Redburn upgraded shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research report on Tuesday, September 16th. Finally, Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a research note on Monday, December 8th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have issued a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $53.33.

Novo Nordisk A/S Stock Down 0.5%

NYSE:NVO opened at $52.29 on Friday. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57. The firm’s 50-day moving average price is $49.35 and its 200-day moving average price is $56.77. The company has a market capitalization of $233.49 billion, a PE ratio of 15.20 and a beta of 0.67. Novo Nordisk A/S has a 1-year low of $43.08 and a 1-year high of $93.80.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, topping the consensus estimate of $0.77 by $0.25. The business had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. On average, equities analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.